Maze Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 31.93 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Details
| Name | Maze Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 141 |
| Founded | 2018 |
| Ipo Date | 2025-01-31 |
| Ceo | Jason Coloma |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US5787841007 |
| Cusip | 578784100 |
| Cik | 1842295 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | Chief Executive Officer and Director |
| Misbah Tahir CPA | Chief Financial Officer and Principal Accounting Officer |
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Vipin Vijayakumar | Senior Vice President of Technology and Business Operations |
| Maarten Hoek | Chief Scientific Officer |
| Courtney J. Phillips J.D. | General Counsel and Corporate Secretary |
| Matt Krause | Senior Vice President of Human Resources |
| Atul Dandekar | Chief Strategy and Business Officer |
| Nazila Habibizad | Senior Vice President of Technical Operations and Supply Chain |
| Winston Tse | Senior Vice President of Drug Discovery |
Contact
| Address | 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080, United States |
| Phone | 650 850 5070 |
| Website | https://www.mazetx.com |